Compare SNDR & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDR | FOLD |
|---|---|---|
| Founded | 1935 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.4B |
| IPO Year | 2017 | 2007 |
| Metric | SNDR | FOLD |
|---|---|---|
| Price | $29.49 | $14.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 10 |
| Target Price | ★ $28.64 | $26.11 |
| AVG Volume (30 Days) | 787.2K | ★ 10.2M |
| Earning Date | 01-29-2026 | 02-18-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | ★ 0.60 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $5,613,800,000.00 | $598,704,000.00 |
| Revenue This Year | $10.44 | $21.49 |
| Revenue Next Year | $4.64 | $18.46 |
| P/E Ratio | $46.75 | ★ N/A |
| Revenue Growth | 5.46 | ★ 21.28 |
| 52 Week Low | $20.11 | $5.51 |
| 52 Week High | $30.84 | $14.38 |
| Indicator | SNDR | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 60.57 | 81.20 |
| Support Level | $29.44 | $14.30 |
| Resistance Level | $30.54 | $14.36 |
| Average True Range (ATR) | 0.70 | 0.05 |
| MACD | -0.05 | -0.17 |
| Stochastic Oscillator | 61.25 | 20.83 |
Schneider National Inc is a provider of surface transportation and logistics solutions in North America. The Company offers truckload, intermodal, and logistics services to a diverse customer base throughout the continental United States, Canada, and Mexico. The company's segments include Truckload; Intermodal; Logistics and other. It generates maximum revenue from the Truckload segment.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.